Meningeal carcinomatosis from pulmonary adenocarcinoma
Dear Sir, Meningeal carcinomatosis without brain parenchymal involvement is a rare metastatic manifestation of carcinoma lung. CT scan and MRI may help the diagnosis, but a positive cytological examination of the cerebrospinal fluid is confirmatory. Intrathecal chemotherapy with involved field radiotherapy is the mainstay of treatment.
A 60-year-old female presented with left lower lobe lung nodule of a poorly differentiated adenocarcinoma. CT Thorax showed a mass in superior segment of (L) lower lobe involving segmental bronchus and another metastatic nodular lesion in the (L) paraortic region with multiple nodules scattered throughout the (L) lung parenchyma. Following six cycles of Gemcitabine and Carboplatin, a repeat CT scan after six months revealed significant resolution in size of the lesions. Left lower lobectomy with lymph node dissection was performed. Histopathology revealed residual Adenocarcinoma with invasion into visceral pleura with vascular invasion and 3 nodes showing metastasis. Three more cycles of chemotherapy with paclitaxel and carboplatin followed.
Patient first complained of headache four months later but CT brain was normal. She was found to have hypertension and treatment was started for the same. She remained asymptomatic for two months when she presented with headache, vomiting and altered sensorium. CT and MRI Brain were normal. PET scan was normal. CSF Cytology clinched the diagnosis [ Figures 1 and 2 ].
Intrathecal Chemotherapy with Methotrexate and Cytarabine showed some improvement. Patient expired two weeks later.
Meningeal carcinomatosis is a diffuse infiltration of leptomeninges and sub arachnoid spaces by malignant cells metastasizing from systemic cancer. It has a pleomorphic clinical presentation affecting cerebrum, cranial nerves or spinal cord. The probability of Letters to Editor developing meningeal carcinomatosis was 2.7% at three years and 7.8% at five years.
[1] It spreads mainly by hematogenous route and CSF is diagnostic. 30-60% have co-existent parenchymal brain metastasis. Treatment is Intrathecal Chemotherapy -Methotrexate, Cytarabine, Thiotepa.
[2] Intrathecal Gemcitabine has been used in non small cell lung cancer.
[3] Intravenous teniposide may be used along with intrathecal chemotherapy. [4] Involved field radiotherapy is reserved for bulky metastatic disease.
The presentation of meningeal carcinomatosis without systemic metastases is rare. Our patient had a metastatic lung nodule to begin with but the disease was well controlled at the time of presentation with meningeal carcinomatosis. The symptoms of headache, vomiting with raised blood pressure along with normal imaging led to a delay in doing CSF cytology. Meningeal carcinomatosis may prove difficult to diagnose as imaging may be misleading. This warrants a high index of suspicion and early CSF cytology. 
Perspectives on QOL in India
Dear Sir, This is a letter in response to an article in your latest issue.
[1]
This is a nice article on QOL that deserves credit. I would like to congratulate the Editorial team of IJC for taking the initiative in publishing such articles on QOL.
The impact of HNC and its treatment can have a profound effect on the patients' physical function and psychological wellbeing and it is essential that their perspective is taken into account. Questionnaires give a structured snapshot or insight into the patients' point of view. They facilitate multidisciplinary team working with the recognition of poor outcome groups, better in formation for the patients and their careers, and the opportunity to identify problem areas and target intervention/support. QOL is a neglected domain in our country. But if we want to compete with the West, we must try and focus on this area where we are at least 10 to 15 years behind.
The authors have taken great pain to bring out this article. I was especially happy and impressed with the honest efforts at the translation process. However we must keep in mind certain important points that are necessary for a balanced perspective.
The UW-QOL scale is brief and simple scale that arms the clinicians with useful information and can contribute to decision-making based on patient feedback. Moreover, it concerns issues that have been important in the last seven days which are easy to recollect. In addition, it can help in audit, research and assist in the making of patient information leaflets/videos.
The availability of open-ended text in the scale, albeit as a single item, provides yet another avenue of information regarding individual patients. However issues such as speech, saliva, smell, cough and mucous production were not addressed adequately in the questionnaire. This raises an important issue that existing QOL instruments may not be sensitive or specific enough for the especially
